University of Louisville School of Medicine

Elevance Health and AADMD Launch Bold Initiative to Broadly Expand Physician Training on the Care of People with Intellectual and Developmental Disabilities

Retrieved on: 
Wednesday, November 1, 2023
Nursing, People with Disabilities, Practice Management, Other Health, Other Education, General Health, University, Consumer, Health, Education, Knowledge, Spectrum, University of Louisville School of Medicine, Request for proposal, Physician, Intellectual, Immersion, Learning, Rehabilitation, Life expectancy, Curriculum, Down syndrome, American Academy, Developmental Medicine & Child Neurology, Health equity, IDD, RFP, Cerebral palsy, Disability, Elevance Health, Investment, Patient, Pharmaceutical industry, Dentistry

NICHE—Medical was founded by the American Academy of Developmental Medicine and Dentistry (AADMD) in 2009 to provide training to medical students on the care of individuals with IDD.

Key Points: 
  • NICHE—Medical was founded by the American Academy of Developmental Medicine and Dentistry (AADMD) in 2009 to provide training to medical students on the care of individuals with IDD.
  • Through a focus on health equity and the social drivers of health, the project centers people with IDD.
  • With Elevance Health funding and support, AADMD will disburse grants to 28 medical schools over the next five years to support IDD curriculum implementation efforts.
  • This will more than double the number of medical schools that offer training on serving patients with IDD.

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Retrieved on: 
Monday, October 23, 2023
AACR, RAS, Breast, MAPK, Prevalence, Conference, NF1, KRAS, University of Louisville School of Medicine, RAL, DAB2IP, Cancer, Partnership, Breast cancer, University, Downregulation and upregulation, Therapy, American Association for Cancer Research, Pharmaceutical industry

CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

Key Points: 
  • “The RAS pathway continues to be an area of immense interest within the scientific community and biopharmaceutical industry.
  • Due to the prevalence and severity of RAS-driven tumors, there is a high unmet need to discover and develop more broadly acting RAS-targeted compounds.
  • These effects are particularly common in Luminal B breast cancer.
  • As a result, we have developed a series of novel direct Pan-RAS inhibitors that exhibit a distinct binding mechanism to other currently described RAS inhibitors.

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Retrieved on: 
Thursday, October 12, 2023
ASH, GBM, Glioblastoma, ORR, Cleveland Clinic, OS, Society, University of Louisville School of Medicine, Safety, University, HSCT, FDA, Brain, Clinical trial, Immune system, Leukemia, PFS, EBMT, TTP, Hematopoietic stem cell transplantation, European Society for Medical Oncology, Graft-versus-host disease, Progression-free survival, Patient, Pharmaceutical industry, Medical imaging

“Our novel, synergistic immunotherapy approach has demonstrated promising early clinical results in patients with unmet medical needs.

Key Points: 
  • “Our novel, synergistic immunotherapy approach has demonstrated promising early clinical results in patients with unmet medical needs.
  • The primary endpoints of this trial are safety and tolerability, and secondary endpoints include rates of graft versus host disease (GvHD), relapse rate and OS.
  • The University of Louisville and The Cleveland Clinic are the first clinical sites activated to enroll patients.
  • INB-400 was granted Orphan Drug Designation by the FDA in April 2023, marking the first genetically modified gamma-delta T cell therapy to receive this regulatory designation.

Michael Charlton Appointed President and CEO of AtlantiCare Healthcare System

Retrieved on: 
Tuesday, October 3, 2023
American Hospital Association, Interim, Korn Ferry, University, Health administration, AtlantiCare, Health, Patient, Multimedia, Trustee, Brown University, Leadership studies, University of Louisville School of Medicine, Chairperson, EGG, Charlton, Caregiver, Management, Nursing

EGG HARBOR TOWNSHIP, N.J., Oct. 3, 2023 /PRNewswire/ -- AtlantiCare's Board of Trustees has appointed Michael J. Charlton as the President and CEO of the AtlantiCare Health System, after a thorough selection process conducted by Korn Ferry, a preeminent executive search firm. Charlton has been in the role of Interim President and CEO since June 1, 2023.  In this role, Charlton will be responsible for AtlantiCare's operations, development, and strategic growth, leading a team of more than 6,500 individuals in serving the community in five southeastern New Jersey counties. Charlton, a successful local business owner with strong ties to the community, served as a member of the AtlantiCare Board of Directors for more than 14 years, with 6 years as Board Chair, an experience that inspired him to take on national healthcare leadership roles 

Key Points: 
  • EGG HARBOR TOWNSHIP, N.J., Oct. 3, 2023 /PRNewswire/ -- AtlantiCare's Board of Trustees has appointed Michael J. Charlton as the President and CEO of the AtlantiCare Health System, after a thorough selection process conducted by Korn Ferry, a preeminent executive search firm.
  • Charlton has been in the role of Interim President and CEO since June 1, 2023.
  • in Healthcare Administration and Organizational Leadership from the University of Louisville and a Masters in Healthcare Leadership from Brown University.
  • Michael is the ideal leader to guide AtlantiCare through this challenging, ever-evolving new age of healthcare."

Forcefield Therapeutics appoints John Tsai MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 27, 2023
Heart, Amgen, BS, University, Cell death, Therapy, MI, Myocardial infarction, Heart failure, Quality of life, Electrical engineering, Panasonic Executive Partner, CMO, Washington University in St. Louis, Cardiovascular disease, Force field, Novartis, Patient, Risk, University of Louisville School of Medicine, Reperfusion, Mouse, Death, Electricity, Pharmaceutical industry, Syncona

Heart disease continues to be the number one cause of death worldwide, with no currently approved treatments to prevent the death of heart cells following a heart attack

Key Points: 
  • Heart disease continues to be the number one cause of death worldwide, with no currently approved treatments to prevent the death of heart cells following a heart attack
    London UK, 27 September 2023 – Forcefield Therapeutics (“Forcefield Tx”) Ltd, a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes, today announced it has appointed John Tsai MD, Executive Partner at Syncona and most recently President, Global Drug Development and Chief Medical Officer at Novartis, as Chief Executive Officer, effective immediately.
  • John brings over 20 years’ experience in global pharmaceuticals with a proven track record in leading transformational organisational growth and strategy.
  • John holds a BS in Electrical Engineering from Washington University in St. Louis and M.D.
  • John Tsai MD, Chief Executive Officer of Forcefield Therapeutics, commented: “Despite advancements in health care, patients still have a 50% chance of death after an acute heart attack.

The Inner Circle Acknowledges, J. Hudson Garrett, Jr. as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy

Retrieved on: 
Monday, September 11, 2023
Knowledge, American Hospital Association, Society, Infection, Neurocritical Care Society, Hope End, Inner circle, American College of Physicians, Health, Health administration, Journal, Theodore Levitt, Division, Practitioner, Pandemic, Nurse practitioner, Antimicrobial, American College, National Association, Hum Honorary Lifetime Achievement Award, University, Vascular access, Learning, Infectious Diseases Society of America, COVID-19, Georgia State University, Multimedia, Harvard Business Review, University of Louisville School of Medicine, Endemism, Public health, Control, Allied health professions, Society of Critical Care Medicine, Journal of the American Association of Nurse Practitioners, Above, Patient safety, Emergency medical services, Critical Care Medicine (journal), Nursing, Policy, Physician, Medicine

ATLANTA, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, J. Hudson Garrett, Jr. is acknowledged as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy.

Key Points: 
  • ATLANTA, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, J. Hudson Garrett, Jr. is acknowledged as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy.
  • Dr. Garrett Jr. pursued graduate education at Georgia State University where he earned a Ph.D. in Health Care Administration and Policy after earning a Master's degree in Business, Nursing, and Public Health.
  • With more than 22 years of experience in the field, Dr. Garrett Jr. established Community Health Associates in 2005 to bring healthcare professionals lifesaving emergency care and safety training.
  • The primary service the company offers is consulting to the healthcare industry, including providers, leaders, medical device companies, pharmaceutical companies, and others.

Top Rated Physical Therapy Group Secures Partnership with University of Louisville Athletics

Retrieved on: 
Wednesday, August 23, 2023
KFC Yum! Center, 1895 Louisville Athletic Club football team, University of Louisville School of Medicine, CSCS, Partnership, University, Confluence, Jim Patterson Stadium, PRPT, Therapy, Virginia Credit Union Stadium, PT, OCS, MBA, Research, History, MAPP, DNP, Athlete, Occupational therapy, Partner, Patient, Trustee, Sport, Radio, UofL, Dr. Mark & Cindy Lynn Stadium, DPT, Family, FAAN, SCS, Nursing

LOUISVILLE, Ky., Aug. 23, 2023 /PRNewswire-PRWeb/ -- Physical Therapy (PRPT) takes great pride in announcing its first-ever collaboration with the University of Louisville (UofL) and Cardinal Sports as an Official Partner of University of Louisville Athletics for the upcoming 2023-2024 athletic season.

Key Points: 
  • ProRehab Physical Therapy, one of Kentucky's top rated physical and occupation therapy experts, is now a Louisville Athletics sponsor
    LOUISVILLE, Ky., Aug. 23, 2023 /PRNewswire-PRWeb/ -- Physical Therapy (PRPT) takes great pride in announcing its first-ever collaboration with the University of Louisville (UofL) and Cardinal Sports as an Official Partner of University of Louisville Athletics for the upcoming 2023-2024 athletic season.
  • "This partnership aligns perfectly with our mission to positively impact the communities we serve by delivering best-in-class musculoskeletal care and advancing physical therapy practices through evidence-based research."
  • CEO of Confluent Health, Dr. Kristi Henderson, DNP, FAAN, also expressed her enthusiasm for the partnership, stating, "We are excited to see ProRehab Physical Therapy collaborate with University of Louisville Athletics.
  • "The partnership between ProRehab Physical Therapy and University of Louisville Athletics has created a power team between top-tier physical therapists and top-performing collegiate athletes," added Dr. Benz.

Health Career Lab and Coalition Partners Mark Celebrated Program Milestones

Retrieved on: 
Tuesday, August 22, 2023
Other Health, Technology, Human Resources, Education, Training, Physical Therapy, Professional Services, Mental Health, Women, Fitness & Nutrition, Men, Other Technology, Consumer, Nursing, Health, Employment, University, Trainer, Coalition, Health equity, HCL, Organizational culture, Organization, STARS, CHIME, University of Louisville School of Medicine, CEOC, UofL, Growth, Digital literacy, Management, Greater Louisville Inc., Metro United Way

The CHIME program is a collaboration with the region’s largest healthcare employers to provide a 15-week training program for those already serving in healthcare roles and poised for growth.

Key Points: 
  • The CHIME program is a collaboration with the region’s largest healthcare employers to provide a 15-week training program for those already serving in healthcare roles and poised for growth.
  • The STARS program, offered through HCL, will launch its first week-long training program Aug. 28, with sessions held every other week through December.
  • The program is designed to serve those entering healthcare for the first time or returning to healthcare for advancement.
  • HCL has a standing invitation to other organizations with an aligned vision and equal passion for the people of Greater Louisville.

Christopher E. Johnson Appointed Director of Georgia State’s Institute for Health Administration

Retrieved on: 
Tuesday, August 8, 2023
United, University, Veterans' affairs, NSF, Commission, National Science Foundation, Agency for Healthcare Research and Quality, Policy, Business, Association of University Programs in Health Administration, Systems science, Georgia State University, Research, Commission on the Accreditation of Healthcare Management Education, Veteran, United States Department of Veterans Affairs, Business education, Robert Wood Johnson Foundation, Nursing, Student, Publication, Health care, Novartis, J. Mack Robinson College of Business, Robinson College, Cambridge, Health, University of Louisville School of Medicine, Quality, Accreditation, Faculty, Health services research, Healthgrades, Management

Atlanta, Georgia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Christopher E. Johnson has been appointed Joe Taylor Director of the Institute of Health Administration at Georgia State University’s J. Mack Robinson College of Business.

Key Points: 
  • Atlanta, Georgia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Christopher E. Johnson has been appointed Joe Taylor Director of the Institute of Health Administration at Georgia State University’s J. Mack Robinson College of Business.
  • A renowned health services research, policy, and administration scholar, Johnson has deep expertise in investigating healthcare organizations and healthcare outcomes for veterans, underserved populations, and the elderly.
  • “We are thrilled Chris Johnson will lead the Institute for Health Administration,” said Richard D. Phillips, dean of the Robinson College.
  • Johnson holds a doctorate in health services research, policy, and administration from the University of Minnesota and is a graduate of the U.S.

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team

Retrieved on: 
Wednesday, June 28, 2023
Drug development, University, Dermatitis, Drug, Journal of the American Academy of Dermatology, American Academy, Acne, Bristol Myers Squibb, Lupus, Psoriasis, Caritas in veritate, Eli Lilly, JAMA Dermatology, UCB, Baylor University, Journal, Publication, Novartis, Series, University of Louisville School of Medicine, Clinical, Drug reaction with eosinophilia and systemic symptoms, Inflammation, Pharmaceutical industry, Medicine, Dermatology, MD, Pfizer

PALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million. The company previously announced the closing of the initial $50 million in April 2023. In addition, the company also announced the appointment of J. Mark Jackson, MD, as Vice President, Clinical Development. 

Key Points: 
  • The company previously announced the closing of the initial $50 million in April 2023.
  • We are also very pleased Dr. Jackson is joining our organization in a key clinical leadership position.
  • Dr. Jackson joins Evommune from his position as a Clinical Professor of Medicine at the University of Louisville.
  • Dr. Jackson received his undergraduate degree from Baylor University and his medical degree from Texas A&M College of Medicine.